Scope and Claims Dissection for US Patent 7,491,725
US 7,491,725 is a crystal-identity and solid-form patent centered on a single chemical substance class: the “crystalline monohydrate of the compound of formula (IV)”, with scope defined by (i) X-ray powder diffraction (XRPD) fingerprinting, (ii) thermal behavior via DSC and TGA, (iii) unit-cell crystallography, and (iv) a specific crystallization route (ethanol/water cooling crystallization) that may start from an intermediate solvate (butanol solvate).
The independent claim set as provided is effectively built on three pillars:
1) Structure by XRPD (claims 1, 3)
2) Structure by DSC/TGA (claims 2, 9, 12)
3) Manufacture/solid form generation by process conditions (claims 6 and 7), plus downstream formulation uses (claims 4, 13, 14) and purity (claims 8, 15, 16).
What is actually claimed? (Substance scope)
What is “the compound of formula (IV)” in scope?
The claims do not recite the chemical name of formula (IV) in the text provided, but they repeatedly anchor identity to “the compound of formula (IV).” All substantive rights therefore attach only to crystalline monohydrate of that particular formula (IV).
Is the patent limited to monohydrate (vs. other hydrates or anhydrates)?
Yes. The central product is “crystalline monohydrate.” The thermal language also ties to loss of one water of hydration (claims 9, 12), and the process is directed to monohydrate formation from an ethanol/water crystallization.
This framing narrows scope to materials that behave like a single-water hydrate under DSC/TGA, not dihydrates or non-stoichiometric forms.
How does XRPD define infringement boundaries?
XRPD claim architecture
Claims 1 and 3 define the monohydrate by XRPD “substantially in accordance with” the FIG. 1 pattern, with claim 3 further requiring specific peak ranges.
Claim 1
- “Crystalline monohydrate of the compound of formula (IV) characterized by an X-ray powder diffraction pattern substantially in accordance with that shown in FIG. 1.”
This is a pattern-to-figure standard plus a “substantially in accordance with” qualifier, leaving some latitude while still tying the claimed subject matter to a defined diffractogram.
Claim 3 (more specific XRPD constraint)
- Requires an XRPD pattern at about 23°C (CuKα, γ = 1.5418 Å; θ/2θ convention implied by 2θ values).
- Must comprise four or more 2θ values selected from this set (each with tolerance ±0.2):
18.0 ± 0.2
18.4 ± 0.2
19.2 ± 0.2
19.6 ± 0.2
21.2 ± 0.2
24.5 ± 0.2
25.9 ± 0.2
28.0 ± 0.2
Practical scope impact: a material that matches any combination of 4+ peaks from that list with the stated tolerances can fall within the XRPD gate even if additional peaks differ.
How do DSC/TGA define infringement boundaries?
DSC/TGA are built into the claim set
Claims 2, 9, 10, 11, 12 specify thermal signatures linked to water loss.
Claim 2
- Claim 1 crystalline monohydrate characterized by DSC thermogram and TGA substantially in accordance with FIG. 2.
This is again “figure-to-thermal profile” scope.
Claim 9
- DSC: “broad peak between approximately 95°C and 130°C which corresponds to the loss of one water of hydration on thermogravimetric analysis.”
This ties an event window to exact stoichiometry behavior: one water leaves in that thermal window.
Claim 10
- TGA weight loss: 3.48% between 50°C and 175°C.
This is the tightest numeric thermal constraint. Any candidate form that does not show a comparable magnitude and interval risks falling outside.
Claim 11
- DSC further has a peak at about 287°C.
This adds another thermal fingerprint.
Claim 12
- Similar to claim 9 but with a slightly different DSC window: “broad peak between approximately 95°C and 130°C” and loss of one water of hydration.
Claim 12 also becomes a separate independent-style product claim for the thermal-defined monohydrate profile, and then claim 13 is the associated composition.
Unit cell and space group scope (crystallography gate)
Claim 5 defines a lattice fingerprint
Claim 5 specifies unit cell parameters and space group:
- Space group: Pbca
- a = 13.8632 (7) Å
- b = 9.3307 (3) Å
- c = 38.390 (2) Å
- Volume = 4965.9 (4) ų
- Molecules/unit cell: 8
- Density (calculated): 1.354 g/cm³
Scope implication: this claim is a crystallographic embodiment. A monohydrate that shows a distinct polymorph or different lattice parameters does not fall under claim 5, even if it shares some XRPD peaks (unless it also satisfies other claim pathways).
Process claim scope: how the monohydrate is made
Claim 6 (core crystallization route)
“A process for preparing the compound of claim 3 comprising:
- heating and dissolving the compound of formula (IV) in an ethanol/water mixture
- and crystallizing the monohydrate from the ethanol/water mixture as it cools.”
Key scope elements:
- solvent system must be ethanol/water
- must include cooling crystallization to produce the monohydrate
- starting point is compound of formula (IV) (not explicitly the monohydrate)
Claim 7 (solvate handling variant)
Claim 6 further:
- “wherein a butanol solvate of the compound of formula (IV) is dissolved in the ethanol/water mixture.”
So, the process scope includes a substitution in upstream feedstock (starting from a butanol solvate), while still ending with ethanol/water cooling to the monohydrate.
Formulation use scope (downstream rights)
Compositions claimed
- Claim 4: solid pharmaceutical composition containing therapeutically effective amount of claim 3 monohydrate + pharmaceutically acceptable carrier
- Claim 13: solid composition containing therapeutically effective amount of claim 12 monohydrate + carrier
- Claim 14: solid composition containing therapeutically effective amount of claim 9 monohydrate + carrier
Scope implication: once the monohydrate meets claim definition, typical solid oral/solid dosage carrier formulations are within scope, unless carrier conditions cause transformation to a different hydrate/anhydrate during manufacture or storage.
Purity limitations (narrowing elements)
- Claim 8: compound of claim 3 is “substantially pure”
- Claim 15: compound of claim 12 is “substantially pure”
- Claim 16: compound of claim 9 is “substantially pure”
These do not define a numeric purity threshold in the text provided. They are still important because they can create manufacturing and analytical compliance requirements in enforcement.
Claim chart style view: what must be proven for infringement
Product (material) infringement requires meeting at least one defined claim pathway
Below is a practical mapping from claim to evidentiary requirements.
| Claim |
Claim Type |
What must be shown on the accused product |
Tightest gating element |
| 1 |
Product |
XRPD pattern “substantially in accordance” with FIG. 1 |
Figure-based XRPD |
| 3 |
Product |
XRPD at ~23°C includes 4+ peaks from specified set (each ±0.2) |
“4 or more” peaks from exact list |
| 2 |
Product |
DSC/TGA match FIG. 2 |
Figure-based thermal behavior |
| 9 |
Product |
DSC broad peak 95°C-130°C matching loss of 1 water (via TGA) |
“loss of one water” window |
| 10 |
Product |
TGA weight loss 3.48% between 50°C-175°C |
3.48% numeric target |
| 11 |
Product |
DSC peak around 287°C |
287°C peak |
| 12 |
Product |
DSC broad peak 95°C-130°C; loss of one water |
DSC window |
| 5 |
Product |
Unit cell parameters and Pbca match given values |
specific lattice + space group |
| 4/13/14 |
Composition |
solid pharmaceutical composition containing the claimed monohydrate + carrier |
underlying monohydrate identity |
| 6/7 |
Process |
ethanol/water dissolution and cooling crystallization to monohydrate (from compound IV or butanol solvate feed) |
ethanol/water cooling crystallization |
| 8/15/16 |
Product |
“substantially pure” monohydrate |
purity qualifier |
Patent landscape for “scope” of competitive design-arounds
Within the boundaries of the claim set provided, design-around strategies track the claim pillars. Competitors typically attempt to move one of the required fingerprints (XRPD, DSC/TGA, lattice, or process) out of the specified ranges.
1) Alternate solid forms
Because claims are anchored to a monohydrate with one water of hydration and specific XRPD peak sets, likely avoidance routes include:
- a different hydrate stoichiometry (e.g., dihydrate)
- an anhydrate
- a different monohydrate polymorph with altered XRPD and/or unit cell
Why it matters: a different lattice (space group and cell dimensions) can defeat claim 5 even if general monohydrate behavior remains.
2) XRPD peak engineering
Claim 3 does not require all peaks, only “four or more” from the list. A design-around that reduces overlap to fewer than four of those peaks (within ±0.2° tolerance) can avoid claim 3, while still being a monohydrate-like solid form.
However, claim 1 uses “substantially in accordance with FIG. 1,” so a competitor must also avoid matching the overall XRPD pattern, not just the specified peak list.
3) Thermal event engineering
Claim 9/12 and the numeric claim 10 provide thermal guardrails:
- DSC broad peak window (95°C-130°C) tied to one water loss
- TGA weight loss of 3.48% between 50°C and 175°C
- DSC peak around 287°C
A design-around that shifts the water-loss event temperature window or changes the weight loss magnitude can defeat claims 9/10/11/12.
4) Purity and manufacturability
“Substantially pure” is a qualifier that can be operationally attacked. Yet enforcement depends on what “substantially” means in the context of the patent and accused product analytics.
5) Process route changes
Claims 6/7 restrict a particular formation route:
- ethanol/water mixture crystallization upon cooling
- dissolution conditions and (in claim 7) optional butanol solvate feed
A competitor can attempt to make the same solid form using different solvents (or different crystallization triggers) to avoid process claims, while still potentially falling under product claims if the final solid form matches.
What does the landscape look like by claim category?
Because only the claims are provided and no other documents (specifications, dependent claim numbering beyond 16, related filings, family members, or litigations) are included in the input, the landscape here is limited to how this patent’s claims carve out space for competitors and licensees.
Landscape zones created by this patent
1) Crystal-form exclusivity zone
- Defined by XRPD fingerprints, DSC/TGA water loss behavior, and unit cell/space group.
2) Solid-form and formulation zone
- Extends product identity into solid pharmaceutical dosage compositions via claims 4, 13, 14.
3) Process exclusivity zone (limited)
- Applies specifically to ethanol/water dissolution and cooling crystallization (and optional butanol solvate feed).
Key Takeaways
- Core protection is for crystalline monohydrate of the compound of formula (IV), with identity anchored to XRPD (claims 1 and 3) and thermal behavior (claims 2, 9, 10, 11, 12) tied to loss of one water of hydration.
- Claim 3 is the actionable XRPD gate: at ~23°C, the monohydrate must contain 4+ peaks within ±0.2° 2θ from a fixed list.
- Claim 10 adds a numeric TGA constraint: 3.48% weight loss between 50°C and 175°C.
- Claim 5 provides a crystallography lock: Pbca with specified unit cell parameters.
- Process protection (claims 6 and 7) covers ethanol/water dissolution and cooling crystallization to the monohydrate and optional handling of a butanol solvate feed.
- Formulation claims (4, 13, 14) extend the solid-form monopoly into solid pharmaceutical compositions built on the claimed monohydrate.
FAQs
1. What is the main product the patent protects?
The crystalline monohydrate of the compound of formula (IV), defined by XRPD and DSC/TGA signatures.
2. How does claim 3 limit the XRPD pattern?
At ~23°C, the XRPD must include four or more peaks (±0.2° 2θ) chosen from 18.0, 18.4, 19.2, 19.6, 21.2, 24.5, 25.9, and 28.0.
3. What thermal event ties the monohydrate to the claims?
A DSC broad peak between ~95°C and 130°C corresponding to loss of one water of hydration by TGA.
4. What is the numeric TGA constraint in the claims?
A 3.48% weight loss between 50°C and 175°C.
5. Does the patent protect a preparation method or only the final solid?
Both. It includes process claims for ethanol/water cooling crystallization (claims 6 and 7) and product/formulation claims for the crystalline monohydrate and solid compositions.
